To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...
It's worth taking a second look at the healthcare giant.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Zacks Investment Research on MSN
Can Pfizer's new & acquired drugs offset its looming patent cliff?
Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their ...
In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.
Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...
PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...
The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...
The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.
By Jonathan Stempel NEW YORK, Feb 10 (Reuters) - Pfizer agreed to accept $29 million to resolve a dispute with the U.S.
Pfizer made one thing clear this week: It's officially back in the obesity race.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results